Terbinafine

Generic Name: Terbinafine

Brand Names: Lamisil, Silka Cream

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N

CAS Number: 91161-71-6

Unique Ingredient Identifier: G7RIW8S0XP

Background: Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.

Terbinafine hydrochloride was granted FDA approval on 30 December 1992.

Indication: Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by Trichophyton species, Microsporum canis, Epidermophyton floccosum, and Tinea species. Terbinafine hydrochloride also treats yeast infections of the skin caused by Candida species and Malassezia furfur.

Associated Conditions: Onychomycosis, Pityriasis versicolor, Sporotrichosis, Tinea Capitis, Tinea Corporis, Tinea Cruris, Tinea Pedis, Cutaneous candidiasis, Severe Tinea Corporis, Severe Tinea Cruris, Severe Tinea Pedis

Clinical Trials

Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis

Phase 1

Not yet recruiting

Conditions: Fungal Resistance

Interventions: Drug: Terbinafine

First Posted Date: 2024-05-06

Last Posted Date: 2024-05-06

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT06400056

From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

Phase 1

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: Terbinafine
Drug: Placebo
Drug: Tenofovir

First Posted Date: 2024-03-06

Last Posted Date: 2025-02-07

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 36

Registration Number: NCT06295328

Locations: 🇳🇱
Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands

Efficacy and Safety of Terbinafine and Itraconazole

Phase 2

Not yet recruiting

Conditions: Tinea Corporis
Tinea Cruris
Tinea Faciei
Dermatophytoses

Interventions: Drug: Terbinafine Tablets
Drug: Itraconazole

First Posted Date: 2023-05-31

Last Posted Date: 2023-05-31

Lead Sponsor: Dhaka Medical College

Target Recruit Count: 150

Registration Number: NCT05881980

Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis

Phase 1

Completed

Conditions: Onychomycosis

Interventions: Drug: itraconazole
Drug: terbinafine

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-19

Lead Sponsor: Combined Military Hospital Abbottabad

Target Recruit Count: 100

Registration Number: NCT05578950

Locations: 🇵🇰
Cmh Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan

Mycosis Culture Collection From Dermatological Isolated

Active, not recruiting

Conditions: Nail Diseases
Onychomycosis
Resistant Infection

Interventions: Drug: Terbinafine Topical Gel
Drug: Itraconazole 200 mg
Drug: Terbinafine 250 mg
Drug: Ciclopirox Topical Gel
Drug: Amorolfine 50 MG/ML

First Posted Date: 2022-08-01

Last Posted Date: 2024-05-08

Lead Sponsor: University of Rome Tor Vergata

Target Recruit Count: 200

Registration Number: NCT05482763

Locations: 🇮🇹
Tor Vergata Univerisity Hospital, Rome, Italy

Efficacy of Intralesional PRP in Treatment of Onychomycosis

Phase 3

Conditions: Platelet Rich Plasma

Interventions: Biological: intralesional platelet rich plasma
Drug: Oral terbinafine

First Posted Date: 2021-11-22

Last Posted Date: 2021-11-22

Lead Sponsor: Sohag University

Target Recruit Count: 75

Registration Number: NCT05128916

Locations: 🇪🇬
Sohag University Hospital, Sohag, Egypt

Terbinafine Treatment of Axial Spondyloarthropathy

Early Phase 1

Withdrawn

Conditions: Ankylosing Spondylitis
Psoriatic Spondylitis
Axial Spondyloarthritis
Spondylitis Secondary to Inflammatory Bowel Disease
Axial Spondyloarthopathy